DMBT
DMBT is an orally effective anti-tumor metastasis and anti-angiogenesis agent. DMBT downregulates key molecules such as EGFR/p-Akt/HIF-1α/VEGF/MMP-9, inhibits the HIF-1α/VE-cadherin (cadherin)/MMPs and Nrf2/HO-1 signaling pathways, and reduces hypoxia-induced ROS levels as well as the secretion and activity of MMP-9. DMBT inhibits hypoxia-induced vasculogenic mimicry, cancer cell migration, invasion and metastasis, and exhibits no obvious cytotoxicity to normal cells. DMBT reduces the area of laser-induced choroidal neovascularization lesions. DMBT can be used in studies related to breast cancer, melanoma and macular degeneration.
For research use only. We do not sell to patients.
- CAS No.: 1260071-76-8
- Formula: C30H38O17
- Molecular Weight:670.61
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
|
MMP-9 |
HIF-1α |
In Vitro
DMBT (1-16 μM; 6-24 h) reverses hypoxia-induced migration of MDA-MB-231 and MCF-7 human mammary adenocarcinoma cells[1][3].
DMBT (16 μM; 24 h) inhibits hypoxia-induced migration of human mammary adenocarcinoma cell lines MDA-MB-231 and MCF-7[1].
DMBT (16 μM; 24 h) inhibits hypoxia-induced invasion of human breast adenocarcinoma cell lines MDA-MB-231 and MCF-7[1].
DMBT (16 μM; 12-24 h for MDA-MB-231, 5-9 h for MCF-7) inhibits hypoxia-induced vasculogenic mimicry (VM) formation in human breast cancer cell lines MDA-MB-231 and MCF-7[1].
DMBT (16 μM; 24 h) inhibits hypoxia-induced upregulation of HIF-1α, VE-cadherin, MMP-9, MMP-2, Rac1, Cdc42 and p-Akt in MDA-MB-231 human breast adenocarcinoma cells[1].
DMBT (16 μM; 24 h) inhibits hypoxia-induced upregulation of MMP-9, Rac1, Cdc42 and Beclin1, reverses hypoxia-induced downregulation of p-mTOR, and exerts no effect on the expression of HIF-1α and VE-cadherin in MCF-7 human breast adenocarcinoma cells[1].
DMBT (1-80 μM; 48 h) exerts no significant antiproliferative or cytotoxic effects on B16BL6 cells[2].
DMBT (2-8 μM; 48-72 h) significantly inhibits the migration of B16BL6 cells in scratch wound healing assays[2].
DMBT (2-8 μM; 24 h) potently inhibits the invasive ability of B16BL6 cells to penetrate Matrigel-coated Transwell chambers[2].
DMBT (2-8 μM; 24 h) regulates gene expression in B16BL6 cells by downregulating the mRNAs of VEGFA, Akt1 and PIK3r1 and upregulating the mRNA of GSK-3β[2].
DMBT (1-8 μM; 48 h) inhibits the protein expression of VEGF and MMP-9 in B16BL6 cells, while reducing the levels of phosphorylated Akt, GSK-3β, mTOR and total β-catenin[2].
DMBT (2-8 μM; 48 h) reduces the levels of β-catenin in both the cytoplasm and nucleus of B16BL6 cells and inhibits the nuclear translocation of β-catenin[2].
DMBT (0.5-8 μM; 24 h) dose-dependently inhibits the Matrigel invasion of human breast adenocarcinoma MDA-MB-231 cells[3].
DMBT (1-8 μM; 24 h) significantly inhibits the activity and expression of MMP-9 in MDA-MB-231 human breast adenocarcinoma cells, while exerting only weak inhibitory effects on MMP-2[3].
DMBT (2-8 μM; 24 h) dose-dependently inhibits capillary tube formation of HUVEC on Matrigel[3].
DMBT (4-8 μM; 24 h) significantly downregulates the expression of VEGF, p-VEGFR-2, VEGFR-2, p-EGFR, EGFR, and p-Akt in MDA-MB-231 human breast adenocarcinoma cells, but exerts no effect on p-ERK1/2[3].
At high concentrations, DMBT (2-128 μM; 24-72 h) does not significantly reduce the viability of MDA-MB-231 human breast adenocarcinoma cells[3].
DMBT (2-64 μM; 24 h) exhibits no cytotoxicity against MDA-MB-231 human mammary adenocarcinoma cells[3].
DMBT (2-128 µM; 24-72 h) exerts weak inhibitory effects on the viability of ARPE-19 and RF/6A cells[4].
DMBT (32 µM; pre-treated with CoCl2 for 30 min, followed by 24 h incubation) significantly inhibits hypoxia-induced activation of the ERK/Nrf2/HO-1/HIF-1α and Akt/NF-κB/HIF-1α pathways in ARPE-19 cells, with inhibition rates of target proteins ranging from 29.5% to 55.9%[4].
Treatment of hypoxia-induced ARPE-19 cells with DMBT (8-32 µM; 6-24 h) inhibits the migratory capacity of RF/6A choroidal endothelial cells[4].
Treatment with hypoxic conditioned medium from ARPE-19 cells exposed to DMBT (8-32 µM; 6 h) significantly inhibits tube formation in RF/6A choroidal endothelial cells[4].
DMBT (8-32 µM; 30 min pre-incubation, 24 h hypoxic incubation) significantly inhibits hypoxia-induced VEGF secretion by ARPE-19 cells[4].
DMBT (8-32 µM; pre-incubated for 30 minutes followed by hypoxic incubation) reduces hypoxia-induced ROS levels in ARPE-19 cells in a concentration-dependent manner[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human breast adenocarcinoma MDA-MB-231, MCF-7 cells
-
Concentration:16 μM
-
Incubation Time:6, 12, 24 h
-
Result:Reversed hypoxia-induced acceleration of migration distance in both cell lines at 6, 12, and 24 h post-scratch.
-
Cell Line:human breast adenocarcinoma MDA-MB-231, MCF-7 cells
-
Concentration:16 μM
-
Incubation Time:24 h
-
Result:Reduced the number of migrated cells in both cell lines to levels lower than the hypoxic group.
-
Cell Line:human breast adenocarcinoma MDA-MB-231, MCF-7 cells
-
Concentration:16 μM
-
Incubation Time:24 h
-
Result:Reduced the number of invaded cells in both cell lines to levels lower than the hypoxic group.
-
Cell Line:human breast adenocarcinoma MDA-MB-231 cells
-
Concentration:16 μM
-
Incubation Time:24 h
-
Result:Significantly reduced the expression of HIF-1α, VE-cadherin, MMP-9, MMP-2, Rac1, Cdc42, and p-Akt, with no effect on VEGF expression.
-
Cell Line:human breast adenocarcinoma MCF-7 cells
-
Concentration:16 μM
-
Incubation Time:24 h
-
Result:Significantly reduced the expression of MMP-9, Rac1, Cdc42, and Beclin1, while increasing p-mTOR expression, with no effect on HIF-1α, VE-cadherin, or VEGF expression.
-
Cell Line:mouse melanoma B16BL6 cells
-
Concentration:1 μM, 2 μM, 4 μM, 8 μM, 16 μM, 20 μM, 40 μM, 80 μM
-
Incubation Time:48 h
-
Result:Does not significantly decrease cellular viability at any tested concentration.
Shows only 15% inhibition even at the highest concentration of 80 μM.
Exhibits no evident cytotoxicity as verified by trypan blue staining.
-
Cell Line:mouse melanoma B16BL6 cells
-
Concentration:2 μM, 4 μM, 8 μM
-
Incubation Time:48 h, 72 h
-
Result:Reduces B16BL6 cell migration in a concentration-dependent manner compared to untreated controls.
Shows statistically significant inhibition at all tested concentrations.
-
Cell Line:mouse melanoma B16BL6 cells
-
Concentration:2 μM, 4 μM, 8 μM
-
Incubation Time:24 h
-
Result:Markedly suppresses the invasive capability of B16BL6 cells.
Significantly reduces the number of cells penetrating the Matrigel-coated filters at all tested concentrations compared to controls (P < 0.01).
Shows greater inhibitory activity than brartemicin at equivalent concentrations (P < 0.05).
-
Cell Line:mouse melanoma B16BL6 cells
-
Concentration:2 μM, 4 μM, 8 μM
-
Incubation Time:24 h
-
Result:Down-regulates mRNA expression of VEGFA, Akt1, and PIK3r1 in a concentration-dependent manner (P < 0.01 for all tested concentrations).
Up-regulates GSK-3β mRNA expression at 8 μM (P < 0.05).
-
Cell Line:mouse melanoma B16BL6 cells
-
Concentration:1 μM, 2 μM, 4 μM, 8 μM
-
Incubation Time:48 h
-
Result:Reduces protein levels of VEGF (8.4% to 32.4% inhibition) and MMP-9 (25.6% to 68.4% inhibition) in a concentration-dependent manner (P < 0.05 at 4 and 8 μM).
Decreases phosphorylated levels of Akt (9.3% to 32.0% reduction), GSK-3β (29.9% to 54.7% reduction), and mTOR.
Reduces total β-catenin protein levels (P < 0.05 at 4 and 8 μM).
Has no significant effect on total GSK-3β protein levels.
-
Cell Line:mouse melanoma B16BL6 cells
-
Concentration:2 μM, 4 μM, 8 μM
-
Incubation Time:48 h
-
Result:Decreases cytoplasmic β-catenin levels (P < 0.05 at 4 and 8 μM) in a concentration-dependent manner.
Decreases nuclear β-catenin levels (P < 0.05 at 4 μM, P < 0.01 at 8 μM) in a concentration-dependent manner.
-
Cell Line:MDA-MB-231 human breast adenocarcinoma cells
-
Concentration:2, 4, 8, 16, 32, 64 and 128 μM
-
Incubation Time:24 h; 48 h; 72 h
-
Result:Did not significantly decrease cellular viability at any tested concentration or incubation time.
Reduced viability by only 27% at 128 μM for 72 h, with no significant anti-proliferative, cytostatic, or cytotoxic effects observed.
-
Cell Line:MDA-MB-231 human breast adenocarcinoma cells
-
Concentration:2, 4, 8, 16, 32 and 64 μM
-
Incubation Time:24 h
-
Result:Showed no evident cytotoxicity at any tested concentration.
Exhibited no significant difference in viable cell counts compared to untreated controls.
-
Cell Line:MDA-MB-231 human breast adenocarcinoma cells
-
Concentration:0.5, 1, 2, 4 and 8 μM
-
Incubation Time:24 h
-
Result:Dose-dependently reduced the number of invaded cells compared to untreated controls.
Showed statistically significant inhibition at concentrations of 1 μM (P < 0.05) and 2, 4, 8 μM (P < 0.01).
-
Cell Line:MDA-MB-231 human breast adenocarcinoma cells
-
Concentration:1, 2, 4 and 8 μM
-
Incubation Time:24 h
-
Result:Dose-dependently suppressed the expression of VEGF, p-VEGFR-2, VEGFR-2, p-EGFR, and EGFR, with statistically significant reductions at 4 and 8 μM (P < 0.05 or P < 0.01).
Significantly inhibited p-Akt expression at 4 and 8 μM (P < 0.05 or P < 0.01), while total Akt expression was unchanged.
Had no significant effect on p-ERK1/2 expression.
-
Cell Line:ARPE-19 human retinal pigment epithelial cells, RF/6A choroidal endothelial cells
-
Concentration:2, 4, 8, 16, 32, 64 and 128 µM
-
Incubation Time:24 h; 48 h; 72 h
-
Result:Reduced cell viability in a dose-dependent manner in both cell lines, but was non-cytotoxic at concentrations ≤32 µmol/L.
Inhibited viability by 13.2% in ARPE-19 cells and 17.6% in RF/6A cells at the highest concentration of 128 µmol/L for 72 h.
-
Cell Line:RF/6A choroidal endothelial cells treated with ARPE-19 cell hypoxia-conditioned medium
-
Concentration:8 and 32 µM
-
Incubation Time:6 h; 12 h; 24 h
-
Result:Had no significant effect on RF/6A cell migration under direct hypoxia.
Significantly restricted migration by 29.82% after 24 h of incubation with hypoxia-conditioned medium from ARPE-19 cells treated with DMBT.
-
Cell Line:Hypoxic ARPE-19 human retinal pigment epithelial cells
-
Concentration:8 and 32 µM
-
Incubation Time:30 min pre-incubation; 24 h hypoxic incubation
-
Result:Significantly inhibited CoCl2-induced VEGF secretion, which increased VEGF levels to 1.7-fold of the control level.
Suppressed VEGF secretion more potently at 32 µmol/L than the ROS inhibitor NAC (5 mmol/L).
-
Cell Line:Hypoxic ARPE-19 human retinal pigment epithelial cells
-
Concentration:8 and 32 µM
-
Incubation Time:30 min CoCl2 pre-treatment; 24 h incubation
-
Result:Significantly inhibited CoCl2-stimulated activation of p-ERK1/2 (53.6% inhibition), intranuclear Nrf2 (50.2% inhibition), HO-1 (29.5% inhibition), and HIF-1α (55.9% inhibition) at 32 µmol/L.
Reduced accumulation of hypoxia-induced p-Akt, p-NF-κB, and HIF-1α at 32 µmol/L.
In Vivo
DMBT (1-10 mg/kg; p.o.; daily; 14 days) significantly reduces lung metastasis of B16BL6 melanoma cells in C57BL/6J mice by approximately 55% and 57%, respectively[2].
DMBT (1-10 mg/kg; p.o.; daily; 14 days) significantly inhibits lung metastasis of luciferase-expressing B16-F10 melanoma cells in Balb/c-nu mice, as measured by bioluminescence imaging and histology[2].
DMBT (0.2-1 mmol/L; intravitreal; twice over 3 days) significantly reduces laser-induced choroidal neovascularization lesion area and retinal VEGF protein levels in male C57BL/6 mice[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c-nu (female, 6 weeks of age, tail vein injection of MDA-MB-231-luc-D3L2HN human breast adenocarcinoma cells)[1]
-
Dosage:1 mg/kg; 10 mg/kg
-
Administration:p.o.; daily; 14 days
-
Result:Inhibited vasculogenic mimicry formation, resulting in small, thin blood vessels compared to controls with thick, dense blood vessels including VM, mosaic vessels, and endothelial-dependent vessels.
-
Animal Model:C57BL/6J mice (female, 4-6 weeks of age, syngeneic melanoma lung metastasis model via tail vein injection of 1.5×105 B16BL6 melanoma cells)[2]
-
Dosage:1 mg/kg; 10 mg/kg
-
Administration:p.o.; daily; 14 days
-
Result:Reduced the number of lung nodules to 72.7, compared to the control group's 162.1 nodules.
Reduced the number of lung nodules to 69.3, compared to the control group's 162.1 nodules.
Achieved statistically significant inhibition relative to controls (P < 0.01).
-
Animal Model:Balb/c-nu mice (female, 6 weeks of age, melanoma lung metastasis model via tail vein injection of 2×105 B16-F10-luc-G5 luciferase-expressing melanoma cells)[2]
-
Dosage:1 mg/kg; 10 mg/kg
-
Administration:p.o.; daily; 14 days
-
Result:Significantly reduced bioluminescent signal intensity in mice on days 11 and 14 post-inoculation (P < 0.05).
Reduced lung-infiltrating tumor cells relative to controls, confirmed by H&E staining.
-
Animal Model:C57BL/6 (male, 6 weeks of age, laser-induced choroidal neovascularization model)[4]
-
Dosage:0.2 mmol/L; 1 mmol/L
-
Administration:intravitreal; twice over 3 days
-
Result:Significantly reduced laser-induced CNV lesion area at 7 days compared to saline controls.
Reduced lesion area to a similar extent as the positive control 1 µmol/L Endostar (1 mmol/L dose).
Significantly reduced retinal VEGF protein levels relative to untreated CNV controls at 5 days post-photocoagulation (both doses).
Chemical Information
-
CAS No. 1260071-76-8
-
Molecular Weight 670.61
-
Formula C30H38O17
-
SMILES
O=C(C1=C(C(OC)=CC=C1)OC)OC[C@H]([C@H]([C@@H]([C@H]2O)O)O)O[C@@H]2O[C@H]3O[C@@H]([C@H]([C@@H]([C@H]3O)O)O)COC(C4=C(C(OC)=CC=C4)OC)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Scratch/Wound-Healing Migration Assay
The scratch/wound-healing migration assay measures collective migration of adherent cells into an experimentally created cell-free gap in a confluent monolayer. The readout is generated by imaging the gap immediately after scratching and at later time points, then quantifying reduction in wound area, wound width, or percentage closure as cells move into the denuded region. Gap closure reflects cell migration but may also include cell proliferation, so interpretation should distinguish migration-focused conditions from proliferation-driven closure when possible, such as by using short assay windows, serum-controlled conditions, cell counting, or proliferation controls reported in published protocols.
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Neural Crest/Neuronal Cell Migration Explant Assay
Neural crest (NC) and neuronal cell migration explant assays are in vitro systems in which neural tube-derived tissues are cultured to allow premigratory or newly emigrated neural crest cells to undergo epithelial-to-mesenchymal transition (EMT), migrate away from the explant, and form a measurable radial outgrowth that reflects migratory capacity and environmental responsiveness. These assays typically quantify migration by measuring the expansion of cell outgrowth from neural tube or neural plate border explants over time, often comparing early and later timepoints to derive a migration index such as a radius ratio, which reflects net cell dispersal from the explant core. Neural tube explant cultures preserve key aspects of neural crest behavior, including EMT, migration, and early differentiation, making them suitable for assessing intrinsic migratory ability and extrinsic cue dependence. However, studies emphasize that migratory outgrowth from neural tube explants may include non-n
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Chemotaxis Gradient Chamber Assay 1
The chemotaxis gradient chamber assay is based on the principle of observing directional cell migration in response to a stable, linear or quasi-linear concentration gradient of a chemoattractant formed between two fluid reservoirs separated by a narrow observation chamber. Cells placed within the chamber respond to the gradient by polarized movement toward higher chemoattractant concentrations, allowing quantification of chemotactic behavior in real time under microscopy. The classic Zigmond chamber design enables simultaneous visualization of gradient formation and individual cell trajectories, making it suitable for studying leukocyte chemotaxis and other motile cell types in vitro.
-
Under-Agarose Cell Migration Assay
The under-agarose cell migration assay is a classical in vitro chemotaxis method designed to evaluate directed cell movement through a semi-solid agarose matrix toward soluble chemoattractant gradients, enabling visualization and quantification of leukocyte or motile cell migration in a confined 2D-like environment. In this system, cells and chemoattractants are placed in separate wells cut into an agarose gel, allowing diffusion-driven gradient formation that guides directional migration, which is typically assessed by measuring migration distance, cell morphology changes, and accumulation toward the chemoattractant source. This assay has been widely used to study neutrophil and leukocyte chemotaxis as a simple alternative to filter-based migration systems and allows direct microscopic observation of migrating cells under near-physiological confinement conditions.
-
Transwell/Boyden Chamber Migration Assay
The Transwell/Boyden chamber migration assay measures cell movement through a porous membrane separating an upper and lower chamber, usually after a chemoattractant gradient is established by placing cells in the upper chamber and chemoattractant-containing medium in the lower chamber. The readout is generated by quantifying cells that traverse the membrane and appear on the lower membrane surface or in the lower chamber, depending on whether the cell type is adherent or non-adherent. This assay reflects chemotactic or haptotactic migration rather than matrix invasion unless an extracellular-matrix barrier is added to the membrane.
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
3D Collagen/Hydrogel Matrix Migration Assay
The 3D collagen/hydrogel matrix migration assay is based on embedding cells within or on top of a fibrillar collagen type I-rich three-dimensional matrix to model in vivo-like extracellular matrix (ECM) architecture, enabling analysis of cell migration through a physically and biochemically relevant scaffold. In contrast to 2D migration systems, cells in 3D matrices interact with fibrillar collagen networks, requiring coordinated adhesion remodeling and proteolytic or non-proteolytic deformation mechanisms to move through confined spaces, thereby providing a more physiologically relevant readout of invasive and migratory behavior in tissue-like environments. Cell movement in 3D collagen matrices is typically quantified by tracking single-cell trajectories, invasion depth, or matrix penetration over time, reflecting combined effects of cytoskeletal dynamics, cell-ECM adhesion turnover, and ECM remodeling. These systems are widely used to study tumor cell invasion and stromal cell motili
-
Cell invasion
Cell invasion is the ability of cells to migrate from one area to another via the extracellular matrix. Cell invasion is the response of normal and cancer cells to chemical and mechanical stimuli. Before migrating to a new region, the extracellular matrix is degraded by proteases within the cell. Cell invasion often occurs during wound repair, vascularization and inflammation, abnormal tissue invasion, and tumor cell metastasis.
-
Cell-Exclusion Zone Migration Assay
The Cell-Exclusion Zone (CEZ) migration assay is an in vitro 2D cell migration method in which a defined cell-free area is created using removable physical barriers such as silicone stoppers, allowing cells to be seeded around the barrier and subsequently migrate into the cleared zone after barrier removal. This approach enables quantification of collective cell migration by monitoring repopulation of the initially cell-free region over time using microscopy-based imaging. Compared with scratch-based wound healing assays, barrier-based exclusion methods are designed to avoid mechanical damage to the extracellular matrix and reduce injury-induced effects on boundary cells, thereby improving interpretability of migration behavior in vitro. The assay readout is typically the progressive reduction in the cell-free area or the number of cells invading the exclusion zone, reflecting coordinated cell motility relevant to physiological processes such as wound healing, epithelial repair, and ca
-
Chemotaxis Gradient Chamber Assay 2
Chemotaxis gradient chamber assays measure directional cell migration in response to a soluble chemical gradient by imaging cells as they move across a defined observation region; the readout is generated from time-lapse cell trajectories, displacement toward the gradient, forward migration index, trajectory plots, rose/polar plots, and statistical tests of non-random directionality. The Dunn chamber is a direct-viewing glass chamber in which cells migrate across a bridge between control and chemoattractant wells, allowing observation of cells in a linear concentration gradient; related direct-viewing formats include the Insall chamber, which supports defined unidirectional gradients and high numerical-aperture microscopy, and the μ-Slide Chemotaxis chamber, which supports long-term live-cell imaging and gradient characterization with fluorescent dye.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
Purity & Documentation
References
[1]. Li S, et al. Inhibitory effects of compound DMBT on hypoxia-induced vasculogenic mimicry in human breast cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2017 Dec;96:982-992. [Content Brief]
[2]. Tang L, et al. Inhibition of invasion and metastasis by DMBT, a novel trehalose derivative, through Akt/GSK-3β/β-catenin pathway in B16BL6 cells. Chem Biol Interact. 2014 Oct 5;222:7-17. [Content Brief]
[3]. Tang L, et al. Inhibition of angiogenesis and invasion by DMBT is mediated by downregulation of VEGF and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 2013 Jun;56:204-13. [Content Brief]
[4]. Chen S, et al. Anti-neovascularization effects of DMBT in age-related macular degeneration by inhibition of VEGF secretion through ROS-dependent signaling pathway. Molecular and cellular biochemistry. 2018 Nov;448(1-2):225-235. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- DMBT
- 1260071-76-8
- EGFR
- Akt
- MMP
- HIF/HIF Prolyl-Hydroxylase
- mTOR
- VEGFR
- NF-κB
- Reactive Oxygen Species (ROS)
- Cadherin
- melanoma
- B16BL6 cells
- RF/6A choroidal endothelial cells
- MCF-7 human breast adenocarcinoma cells
- MDA-MB-231 human breast adenocarcinoma cells
- choroidal neovascularization
- wet age-related macular degeneration
- HUVECs
- ARPE-19 cells
- breast cancer
- Inhibitor
- inhibitor
- inhibit